When compared to blood, the number of mutant-specific T cells may be enriched in IDH1R132H expressing tumor tissue in case an effective T cell response had occurred [36–39], providing a rationale to screen for the presence of IDH1R132H-specific CD4 T cells among TILs. The gene discussed is CD4; the disease is neoplasm.